Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
1. Novo Nordisk's CEO resigns amid market share loss to Eli Lilly's Zepbound. 2. Eli Lilly's Zepbound now surpasses Wegovy in U.S. prescriptions. 3. Market for weight loss drugs may exceed $150 billion by 2030. 4. Novo Nordisk faces challenges with upcoming patent expiration for Wegovy. 5. Eli Lilly's stock has surged, outperforming Novo Nordisk significantly.